Affimed Reports Progress on Key Clinical Development Programs
IND application submitted for first-in-human study of AFM24, a bispecific EGFR/CD16A innate cell engager for solid tumors FDA clearance of IND for first clinical study of a stable complex of AFM13 pre-mixed with cord blood-derived allogeneic NK cells in …